Our Offerings
By Industry By Function
About Us
Our Viewpoint
NEW
 Senior Management Experts Panel Global Consultants Press Releases Blog
Infographics Market Insights Case Studies Illustrations In The Press
Contact Us
The Business Research Company Logo
Reports Store
Top 50 Healthcare Market Reports
NEW
 Top 50 Non-Healthcare Market Reports
NEW
 Opportunities And Strategies Reports Aerospace And Defense Agriculture Chemicals Construction
Electrical And Electronics Financial Services Food And Beverages Healthcare Services Hospitality Information Technology Machinery Media
Medical Equipment Metal And Mineral Mining Oil And Gas Paper, Plastics, Rubber, Wood And Textile Pharmaceuticals Professional Services Recreation
Retail And Wholesale Services Social Services Transport Transport Services Utilities Veterinary Healthcare Filter Reports by Trends
NEW
Market Intelligence Platform
About GMM Global Forecast
NEW
 Mega Trends Analysis
Consultancies Corporate Planning & Strategy Academic Financial Services Legal Services
Pricing Methodology Sources FAQ Press Coverage
Customized Research
Find Customers Optimise Your Marketing Mix Evaluate Competitors Identify Market Opportunities Develop Products And Services
Distributor And Partner Research Plan Finances Streamline Your Operations Devise Market Entry Strategy Explore Custom Research Packages
NEW
Continuous Research
Desk Research Research Reports Senior Executive Interviews Consumer Research Market Sizing And Forecasts
Company Information Analytics And Data Visualization Research Automation Web Crawling And Spidering AI-Empowered Research Services
Request Proposal
Neurological Disorder Drugs Global Market Report 2025
Download Free Sample Buy Now
Global Neurological Disorder Drugs Market Report 2025

Report Price : $4490.00

Pages : 175

Format : PDF

Published : December 2025

Delivery Time : 2-3 Business Days

Purchase This Report Download Sample PDF
Purchase This Report

Neurological Disorder Drugs Global Market Report 2025

By Drug Class (Cholinesterase Inhibitors, N-Methyl-D-Aspartate (NMDA) Receptor Antagonists, Antiepileptic, Antipsychotic And Antidepressant, Other Drugs Classes), By Indication (Epilepsy, Alzheimer’s Disease, Parkinson’s Disease, Multiple Sclerosis, Cerebrovascular Disease, Other Indications), By Route Of Administration (Oral, Parenteral, Other Routes Of Administration), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Other Distribution Channels), By End-Users (Hospitals, Specialty Clinics, Homecare, Other End Users) – Impact of Tariff and Trade War on Market Size, Growth, Trends, and Forecast 2025–2034

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

Neurological Disorder Drugs Market Overview

• Neurological Disorder Drugs market size has reached to $84.6 billion in 2024

• Expected to grow to $110.99 billion in 2029 at a compound annual growth rate (CAGR) of 5.6%

• Growth Driver: Rising Neurological Disorders Drive Growth In Drugs Market

• Market Trend: Innovative Approaches In Neurological Disorder Drugs Advancing Treatment For Multiple Sclerosis

• North America was the largest region in 2024 and Asia-Pacific is the fastest growing region.

What Is Covered Under Neurological Disorder Drugs Market?

Neurological disorder drugs refer to medications used to treat disorders of the nervous system. These disorders can affect the brain, spinal cord, and nerves throughout the body. The drugs aim to manage symptoms, slow the progression of the disorder, and improve the quality of life for individuals affected.

The main types of drug classes in neurological disorders are cholinesterase inhibitors, N-Methyl-D-Aspartate (NMDA) receptor antagonists, antiepileptics, antipsychotics, antidepressants, and others. Cholinesterase inhibitors are medications that prevent the breakdown of acetylcholine, a neurotransmitter involved in memory and cognitive function. Which can be used for various indications such as epilepsy, alzheimer’s disease, parkinson’s disease, multiple sclerosis, cerebrovascular disease, and others, through various routes of administration, including oral, parenteral, and others. And these can be distributed through various channels, including hospital pharmacies, retail pharmacies, online pharmacies, and others, and end users are hospitals, specialty clinics, home care, and others.

Neurological Disorder Drugs Market Size and growth rate 2025 to 2029: Graph

What Is The Neurological Disorder Drugs Market Size 2025 And Growth Rate?

The neurological disorder drugs market size has grown strongly in recent years. It will grow from $84.6 billion in 2024 to $89.24 billion in 2025 at a compound annual growth rate (CAGR) of 5.5%. The growth in the historic period can be attributed to increasing animal testing and obtaining promising results, an increase in therapeutic treatments, the growth of neurological problems, government initiatives, and a growth in healthcare expenditure.

What Is The Neurological Disorder Drugs Market Growth Forecast?

The neurological disorder drugs market size is expected to see strong growth in the next few years. It will grow to $110.99 billion in 2029 at a compound annual growth rate (CAGR) of 5.6%. The growth in the forecast period can be attributed to expanding therapeutic options and personalized therapies, a growing focus on disease-modifying treatments, the expanding use of digital biomarkers, and the increasing prevalence of neurological diseases. Major trends in the forecast period include advancements in drug design, advancements in neuroimaging, advancements in genetic research, collaborations and licensing agreements, and the emergence of regenerative medicine.

The forecast of 5.6% growth over the next five years reflects a modest reduction of 0.6% from the previous estimate for this market. This reduction is primarily due to the impact of tariffs between the US and other countries. Tariff barriers may strain U.S. epilepsy clinics by increasing the cost of antiepileptics and neurotransmitter modulators sourced from Israel and India, potentially reducing seizure control options and elevating neurology care expenses. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

Customer representative image Book your 30 minutes free consultation with our research experts
Contact Us

What’s The Trade War Impact On Pharmaceuticals Industry?

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the pharmaceutical companies contend with tariffs on APIs, glass vials, and lab equipment inputs with few alternative sources. Generic drug makers, operating on razor-thin margins, are especially vulnerable, with some reducing production of low-profit medicines. Biotech firms face delays in clinical trials due to tariff-related shortages of specialized reagents. In response, the industry is expanding API production in India and Europe, increasing inventory stockpiles, and pushing for trade exemptions for essential medicines.

How Is The Neurological Disorder Drugs Market Segmented?

1) By Drug Class: Cholinesterase Inhibitors, N-Methyl-D-Aspartate (NMDA) Receptor Antagonists, Antiepileptic, Antipsychotic And Antidepressant, Other Drugs Classes

2) By Indication: Epilepsy, Alzheimer’s Disease, Parkinson’s Disease, Multiple Sclerosis, Cerebrovascular Disease, Other Indications

3) By Route Of Administration: Oral, Parenteral, Other Routes Of Administration

4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Other Distribution Channels

5) By End-Users: Hospitals, Specialty Clinics, Homecare, Other End Users

Subsegtments:

1) By Cholinesterase Inhibitors: Donepezil, Rivastigmine, Galantamine

2) By N-Methyl-D-Aspartate (NMDA) Receptor Antagonists: Memantine, Other NMDA Receptor Antagonists

3) By Antiepileptic: Sodium Channel Blockers, GABA Enhancers, Glutamate Modulators, Other Antiepileptics

4) By Antipsychotic and Antidepressant: Risperidone, olanzapine, SSRIs, SNRIs, Tricyclic

5) By Other Drug Classes: Dopaminergic Drugs, Alpha-2 Agonists, Immunomodulators, Other Neurological Disorder Medications

What Is Driving The Neurological Disorder Drugs Market? Rising Neurological Disorders Drive Growth In Drugs Market

The increasing prevalence of neurological diseases is expected to propel the growth of the neurological disorder drugs market going forward. Neurological disorders refer to the conditions affecting the brain, spinal cord, and nerves caused by structural, biochemical, or electrical abnormalities, leading to various symptoms. The increase in neurological diseases is attributed to the aging global population and greater exposure to environmental, metabolic, and lifestyle risk factors. Neurological disorder drugs play a critical role in managing these complex conditions, offering relief from symptoms, slowing disease progression, and improving long-term outcomes for patients. For instance, in September 2024, according to the Australian Institute of Health and Welfare, an Australia-based government agency, IT is projected that the number of people living with dementia in Australia will more than double between 2023 and 2058, increasing from approximately 411,100 in 2023 to 849,300 by 2058, with around 315,500 men and 533,800 women affected. Therefore, the increasing prevalence of neurological disease is driving the growth of the neurological disorder drugs industry.

Who Are The Major Players In The Global Neurological Disorder Drugs Market?

Major companies operating in the neurological disorder drugs market are F. Hoffmann-La Roche Ltd, Bayer AG, Sanofi S.A, AstraZeneca PLC, Abbott Laboratories, Novartis AG, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company Pvt Ltd, Amgen Inc, Boehringer Ingelheim GmbH, Novo Nordisk A/S, Merck KGaA, Teva Pharmaceutical Industries Ltd, Otsuka America Pharmaceutical Inc, Biogen Inc, Bausch Health Companies Inc, Alexion Pharmaceuticals Inc., UCB S.A., Eisai Co Ltd, Cipla Inc, BioMarin Pharmaceutical Inc., Biocon Ltd, Acorda Therapeutics Inc.

What Are The Key Trends Of The Global Neurological Disorder Drugs Market? Innovative Approaches In Neurological Disorder Drugs Advancing Treatment For Multiple Sclerosis

Major companies operating in the neurological disorder drugs market are focusing on developing innovative Ocrelizumab drug therapies to enhance treatment efficacy, improve patient outcomes, and expand therapeutic options for individuals with multiple sclerosis. Ocrelizumab is a humanized monoclonal antibody used as a therapeutic drug in the treatment of multiple sclerosis (MS), a type of neurological disorder. For instance, in February 2024, Roche Holding AG, a Switzerland-based pharmaceutical company, launched Ocrevus (Ocrelizumab), a new disease-modifying therapy (DMT) drug for the treatment of multiple sclerosis in India. Ocrevus is the first and only approved DMT for both relapsing-remitting multiple sclerosis (RRMS) and primary progressive multiple sclerosis (PPMS), based on over 10 years of clinical and real-world data. It is a monoclonal antibody that targets CD20-positive B cells, which are believed to play a role in the autoimmune attack on the central nervous system in multiple sclerosis (MS). Ocrevus is used to treat both relapsing-remitting MS (RRMS) and primary progressive MS (PPMS), making IT the first drug approved for both forms of the disease. It is administered intravenously, typically every six months, and has shown efficacy in reducing disease activity and disability progression in clinical trials.

Need data on a specific region in this market?
Request Regional Data

What Are Latest Mergers And Acquisitions In The Neurological Disorder Drugs Market? Pfizer's Acquisition Of Biohaven Pharmaceuticals Enhancing Global Leadership In Migraine Treatments

In October 2022, Pfizer Inc., a US-based pharmaceutical company, acquired Biohaven Pharmaceuticals for $11.6 billion. Through this acquisition, Pfizer aims to strengthen its innovative internal medicine pipeline and global reach in migraine treatments by gaining access to Biohaven's breakthrough calcitonin gene-related peptide portfolio, including the approved NURTEC ODT and pipeline assets such as Zavegepant. Pfizer aims to deliver these innovative therapies to over 1 billion people worldwide affected by migraine. Biohaven Pharmaceutical is a US-based, clinical-stage biopharmaceutical company that offers a range of neurological and neuropsychiatric disorder drugs.

What Is The Regional Outlook For The Global Neurological Disorder Drugs Market?

North America was the largest region in the neurological disorder drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Neurological Disorder Drugs Market?

The neurological disorder drugs market consists of sales of antiepileptic drugs, dopaminergic agents, cholinesterase inhibitors, immunomodulatory drugs, and antipsychotic drugs. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What is the Market Assessment and Strategic Outlook for the Neurological Disorder Drugs Industry?

The neurological disorder drugs market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the neurological disorder drugs industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.

Neurological Disorder Drugs Market Report Forecast Analysis

Report AttributeDetails
Market Size Value In 2025 $89.24 billion
Revenue Forecast In 2034 $110.99 billion
Growth Rate CAGR of 5.6% from 2025 to 2034
Base Year For Estimation 2024
Actual Estimates/Historical Data 2019-2024
Forecast Period 2025 - 2029 - 2034
Market Representation Revenue in USD Billion and CAGR from 2025 to 2034
Segments Covered 1) By Drug Class: Cholinesterase Inhibitors, N-Methyl-D-Aspartate (NMDA) Receptor Antagonists, Antiepileptic, Antipsychotic And Antidepressant, Other Drugs Classes
2) By Indication: Epilepsy, Alzheimer’s Disease, Parkinson’s Disease, Multiple Sclerosis, Cerebrovascular Disease, Other Indications
3) By Route Of Administration: Oral, Parenteral, Other Routes Of Administration
4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Other Distribution Channels
5) By End-Users: Hospitals, Specialty Clinics, Homecare, Other End Users Subsegtments: 1) By Cholinesterase Inhibitors: Donepezil, Rivastigmine, Galantamine
2) By N-Methyl-D-Aspartate (NMDA) Receptor Antagonists: Memantine, Other NMDA Receptor Antagonists
3) By Antiepileptic: Sodium Channel Blockers, GABA Enhancers, Glutamate Modulators, Other Antiepileptics
4) By Antipsychotic and Antidepressant: Risperidone, Olanzapine, SSRIs, SNRIs, Tricyclic
5) By Other Drug Classes: Dopaminergic Drugs, Alpha-2 Agonists, Immunomodulators, Other Neurological Disorder Medications
Regional Scope Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Country Scope The countries covered in the report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain. Additional countries that can be covered in the report are Bangladesh, Thailand, Vietnam, Malaysia, Singapore, Philippines, Hong Kong, New Zealand, Mexico, Chile, Argentina, Colombia, Peru, Austria, Belgium, Denmark, Finland, Ireland, Netherlands, Norway, Portugal, Sweden, Switzerland, Czech Republic, Poland, Romania, Ukraine, Saudi Arabia, Israel, Iran, Turkey, UAE, Egypt, Nigeria, South Africa.
Key Companies Profiled F. Hoffmann-La Roche Ltd, Bayer AG, Sanofi S.A, AstraZeneca PLC, Abbott Laboratories, Novartis AG, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company Pvt Ltd, Amgen Inc, Boehringer Ingelheim GmbH, Novo Nordisk A/S, Merck KGaA, Teva Pharmaceutical Industries Ltd, Otsuka America Pharmaceutical Inc, Biogen Inc, Bausch Health Companies Inc, Alexion Pharmaceuticals Inc., UCB S.A., Eisai Co Ltd, Cipla Inc, BioMarin Pharmaceutical Inc., Biocon Ltd, Acorda Therapeutics Inc.
Customization ScopeRequest for Sample
Pricing And Purchase OptionsExplore Purchase Options

Table Of Contents

1. Executive Summary

2. Neurological Disorder Drugs Market Characteristics

3. Neurological Disorder Drugs Market Trends And Strategies

4. Neurological Disorder Drugs Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

4.1. Supply Chain Impact from Tariff War & Trade Protectionism

5. Global Neurological Disorder Drugs Growth Analysis And Strategic Analysis Framework

5.1. Global Neurological Disorder Drugs PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)

5.2. Analysis Of End Use Industries

5.3. Global Neurological Disorder Drugs Market Growth Rate Analysis

5.4. Global Neurological Disorder Drugs Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)

5.5. Global Neurological Disorder Drugs Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)

5.6. Global Neurological Disorder Drugs Total Addressable Market (TAM)

6. Neurological Disorder Drugs Market Segmentation

6.1. Global Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Cholinesterase Inhibitors

N-Methyl-D-Aspartate (NMDA) Receptor Antagonists

Antiepileptic

Antipsychotic And Antidepressant

Other Drugs Classes

6.2. Global Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Epilepsy

Alzheimer’s Disease

Parkinson’s Disease

Multiple Sclerosis

Cerebrovascular Disease

Other Indications

6.3. Global Neurological Disorder Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Oral

Parenteral

Other Routes Of Administration

6.4. Global Neurological Disorder Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Hospital Pharmacy

Retail Pharmacy

Online Pharmacy

Other Distribution Channels

6.5. Global Neurological Disorder Drugs Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Hospitals

Specialty Clinics

Homecare

Other End Users

6.6. Global Neurological Disorder Drugs Market, Sub-Segmentation Of Cholinesterase Inhibitors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Donepezil

Rivastigmine

Galantamine

6.7. Global Neurological Disorder Drugs Market, Sub-Segmentation Of N-Methyl-D-Aspartate (NMDA) Receptor Antagonists, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Memantine

Other NMDA Receptor Antagonists

6.8. Global Neurological Disorder Drugs Market, Sub-Segmentation Of Antiepileptic, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Sodium Channel Blockers

GABA Enhancers

Glutamate Modulators

Other Antiepileptics

6.9. Global Neurological Disorder Drugs Market, Sub-Segmentation Of Antipsychotic and Antidepressant, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Risperidone

Olanzapine

SSRIs

SNRIs

Tricyclic

6.10. Global Neurological Disorder Drugs Market, Sub-Segmentation Of Other Drug Classes, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Dopaminergic Drugs

Alpha-2 Agonists

Immunomodulators

Other Neurological Disorder Medications

7. Neurological Disorder Drugs Market Regional And Country Analysis

7.1. Global Neurological Disorder Drugs Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

7.2. Global Neurological Disorder Drugs Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Neurological Disorder Drugs Market

8.1. Asia-Pacific Neurological Disorder Drugs Market Overview

Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

8.2. Asia-Pacific Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8.3. Asia-Pacific Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8.4. Asia-Pacific Neurological Disorder Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Neurological Disorder Drugs Market

9.1. China Neurological Disorder Drugs Market Overview

9.2. China Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

9.3. China Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

9.4. China Neurological Disorder Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Neurological Disorder Drugs Market

10.1. India Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

10.2. India Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

10.3. India Neurological Disorder Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Neurological Disorder Drugs Market

11.1. Japan Neurological Disorder Drugs Market Overview

11.2. Japan Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11.3. Japan Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11.4. Japan Neurological Disorder Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Neurological Disorder Drugs Market

12.1. Australia Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12.2. Australia Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12.3. Australia Neurological Disorder Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Neurological Disorder Drugs Market

13.1. Indonesia Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13.2. Indonesia Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13.3. Indonesia Neurological Disorder Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Neurological Disorder Drugs Market

14.1. South Korea Neurological Disorder Drugs Market Overview

14.2. South Korea Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14.3. South Korea Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14.4. South Korea Neurological Disorder Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Neurological Disorder Drugs Market

15.1. Western Europe Neurological Disorder Drugs Market Overview

15.2. Western Europe Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15.3. Western Europe Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15.4. Western Europe Neurological Disorder Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Neurological Disorder Drugs Market

16.1. UK Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16.2. UK Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16.3. UK Neurological Disorder Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Neurological Disorder Drugs Market

17.1. Germany Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17.2. Germany Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17.3. Germany Neurological Disorder Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Neurological Disorder Drugs Market

18.1. France Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18.2. France Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18.3. France Neurological Disorder Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Neurological Disorder Drugs Market

19.1. Italy Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19.2. Italy Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19.3. Italy Neurological Disorder Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Neurological Disorder Drugs Market

20.1. Spain Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20.2. Spain Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20.3. Spain Neurological Disorder Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Neurological Disorder Drugs Market

21.1. Eastern Europe Neurological Disorder Drugs Market Overview

21.2. Eastern Europe Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21.3. Eastern Europe Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21.4. Eastern Europe Neurological Disorder Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Neurological Disorder Drugs Market

22.1. Russia Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22.2. Russia Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22.3. Russia Neurological Disorder Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Neurological Disorder Drugs Market

23.1. North America Neurological Disorder Drugs Market Overview

23.2. North America Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23.3. North America Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23.4. North America Neurological Disorder Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Neurological Disorder Drugs Market

24.1. USA Neurological Disorder Drugs Market Overview

24.2. USA Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24.3. USA Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24.4. USA Neurological Disorder Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Neurological Disorder Drugs Market

25.1. Canada Neurological Disorder Drugs Market Overview

25.2. Canada Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25.3. Canada Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25.4. Canada Neurological Disorder Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Neurological Disorder Drugs Market

26.1. South America Neurological Disorder Drugs Market Overview

26.2. South America Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26.3. South America Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26.4. South America Neurological Disorder Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Neurological Disorder Drugs Market

27.1. Brazil Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27.2. Brazil Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27.3. Brazil Neurological Disorder Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Neurological Disorder Drugs Market

28.1. Middle East Neurological Disorder Drugs Market Overview

28.2. Middle East Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28.3. Middle East Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28.4. Middle East Neurological Disorder Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Neurological Disorder Drugs Market

29.1. Africa Neurological Disorder Drugs Market Overview

29.2. Africa Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29.3. Africa Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29.4. Africa Neurological Disorder Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Neurological Disorder Drugs Market Competitive Landscape And Company Profiles

30.1. Neurological Disorder Drugs Market Competitive Landscape

30.2. Neurological Disorder Drugs Market Company Profiles

30.2.1. F. Hoffmann-La Roche Ltd Overview, Products and Services, Strategy and Financial Analysis

30.2.2. Bayer AG Overview, Products and Services, Strategy and Financial Analysis

30.2.3. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis

30.2.4. AstraZeneca PLC Overview, Products and Services, Strategy and Financial Analysis

30.2.5. Abbott Laboratories Overview, Products and Services, Strategy and Financial Analysis

31. Neurological Disorder Drugs Market Other Major And Innovative Companies

31.1. Novartis AG

31.2. GlaxoSmithKline plc

31.3. Takeda Pharmaceutical Company Limited

31.4. Eli Lilly and Company Pvt Ltd

31.5. Amgen Inc.

31.6. Boehringer Ingelheim GmbH

31.7. Novo Nordisk A/S

31.8. Merck KGaA

31.9. Teva Pharmaceutical Industries Ltd.

31.10. Otsuka America Pharmaceutical Inc.

31.11. Biogen Inc.

31.12. Bausch Health Companies Inc.

31.13. Alexion Pharmaceuticals Inc.

31.14. UCB S.A.

31.15. Eisai Co. Ltd.

32. Global Neurological Disorder Drugs Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Neurological Disorder Drugs Market

34. Recent Developments In The Neurological Disorder Drugs Market

35. Neurological Disorder Drugs Market High Potential Countries, Segments and Strategies

35.1 Neurological Disorder Drugs Market In 2029 - Countries Offering Most New Opportunities

35.2 Neurological Disorder Drugs Market In 2029 - Segments Offering Most New Opportunities

35.3 Neurological Disorder Drugs Market In 2029 - Growth Strategies

35.3.1 Market Trend Based Strategies

35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations

36.2. Currencies

36.3. Historic And Forecast Inflation Rates

36.4. Research Inquiries

36.5. The Business Research Company

36.6. Copyright And Disclaimer

List Of Tables

    Table 1: Global Historic Market Growth, 2019-2024, $ Billion
  • Table 2: Global Forecast Market Growth, 2024-2029F, 2034F, $ Billion
  • Table 3: Global Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 4: Global Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 5: Global Neurological Disorder Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 6: Global Neurological Disorder Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 7: Global Neurological Disorder Drugs Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 8: Global Neurological Disorder Drugs Market, Sub-Segmentation Of Cholinesterase Inhibitors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 9: Global Neurological Disorder Drugs Market, Sub-Segmentation Of N-Methyl-D-Aspartate (NMDA) Receptor Antagonists, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 10: Global Neurological Disorder Drugs Market, Sub-Segmentation Of Antiepileptic, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 11: Global Neurological Disorder Drugs Market, Sub-Segmentation Of Antipsychotic and Antidepressant, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 12: Global Neurological Disorder Drugs Market, Sub-Segmentation Of Other Drug Classes, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 13: Global Neurological Disorder Drugs Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 14: Global Neurological Disorder Drugs Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 15: Asia-Pacific, Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 16: Asia-Pacific, Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 17: Asia-Pacific, Neurological Disorder Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 18: China, Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 19: China, Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 20: China, Neurological Disorder Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 21: India, Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 22: India, Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 23: India, Neurological Disorder Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 24: Japan, Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 25: Japan, Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 26: Japan, Neurological Disorder Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 27: Australia, Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 28: Australia, Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 29: Australia, Neurological Disorder Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 30: Indonesia, Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 31: Indonesia, Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 32: Indonesia, Neurological Disorder Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 33: South Korea, Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 34: South Korea, Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 35: South Korea, Neurological Disorder Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 36: Western Europe, Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 37: Western Europe, Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 38: Western Europe, Neurological Disorder Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 39: UK, Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 40: UK, Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 41: UK, Neurological Disorder Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 42: Germany, Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 43: Germany, Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 44: Germany, Neurological Disorder Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 45: France, Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 46: France, Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 47: France, Neurological Disorder Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 48: Italy, Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 49: Italy, Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 50: Italy, Neurological Disorder Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 51: Spain, Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 52: Spain, Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 53: Spain, Neurological Disorder Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 54: Eastern Europe, Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 55: Eastern Europe, Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 56: Eastern Europe, Neurological Disorder Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 57: Russia, Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 58: Russia, Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 59: Russia, Neurological Disorder Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 60: North America, Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 61: North America, Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 62: North America, Neurological Disorder Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 63: USA, Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 64: USA, Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 65: USA, Neurological Disorder Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 66: Canada, Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 67: Canada, Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 68: Canada, Neurological Disorder Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 69: South America, Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 70: South America, Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 71: South America, Neurological Disorder Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 72: Brazil, Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 73: Brazil, Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 74: Brazil, Neurological Disorder Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 75: Middle East, Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 76: Middle East, Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 77: Middle East, Neurological Disorder Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 78: Africa, Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 79: Africa, Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 80: Africa, Neurological Disorder Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 81: F. Hoffmann-La Roche Ltd Financial Performance
  • Table 82: Bayer AG Financial Performance
  • Table 83: Sanofi S.A. Financial Performance
  • Table 84: AstraZeneca PLC Financial Performance
  • Table 85: Abbott Laboratories Financial Performance

List Of Figures

    Figure 1: Global Historic Market Growth, 2019-2024, $ Billion
  • Figure 2: Global Forecast Market Growth, 2024-2029F, 2034F, $ Billion
  • Figure 3: Global Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 4: Global Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 5: Global Neurological Disorder Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 6: Global Neurological Disorder Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 7: Global Neurological Disorder Drugs Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 8: Global Neurological Disorder Drugs Market, Sub-Segmentation Of Cholinesterase Inhibitors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 9: Global Neurological Disorder Drugs Market, Sub-Segmentation Of N-Methyl-D-Aspartate (NMDA) Receptor Antagonists, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 10: Global Neurological Disorder Drugs Market, Sub-Segmentation Of Antiepileptic, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 11: Global Neurological Disorder Drugs Market, Sub-Segmentation Of Antipsychotic and Antidepressant, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 12: Global Neurological Disorder Drugs Market, Sub-Segmentation Of Other Drug Classes, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 13: Global Neurological Disorder Drugs Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 14: Global Neurological Disorder Drugs Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 15: Asia-Pacific, Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 16: Asia-Pacific, Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 17: Asia-Pacific, Neurological Disorder Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 18: China, Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 19: China, Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 20: China, Neurological Disorder Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 21: India, Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 22: India, Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 23: India, Neurological Disorder Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 24: Japan, Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 25: Japan, Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 26: Japan, Neurological Disorder Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 27: Australia, Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 28: Australia, Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 29: Australia, Neurological Disorder Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 30: Indonesia, Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 31: Indonesia, Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 32: Indonesia, Neurological Disorder Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 33: South Korea, Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 34: South Korea, Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 35: South Korea, Neurological Disorder Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 36: Western Europe, Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 37: Western Europe, Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 38: Western Europe, Neurological Disorder Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 39: UK, Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 40: UK, Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 41: UK, Neurological Disorder Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 42: Germany, Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 43: Germany, Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 44: Germany, Neurological Disorder Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 45: France, Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 46: France, Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 47: France, Neurological Disorder Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 48: Italy, Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 49: Italy, Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 50: Italy, Neurological Disorder Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 51: Spain, Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 52: Spain, Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 53: Spain, Neurological Disorder Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 54: Eastern Europe, Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 55: Eastern Europe, Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 56: Eastern Europe, Neurological Disorder Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 57: Russia, Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 58: Russia, Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 59: Russia, Neurological Disorder Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 60: North America, Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 61: North America, Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 62: North America, Neurological Disorder Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 63: USA, Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 64: USA, Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 65: USA, Neurological Disorder Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 66: Canada, Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 67: Canada, Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 68: Canada, Neurological Disorder Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 69: South America, Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 70: South America, Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 71: South America, Neurological Disorder Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 72: Brazil, Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 73: Brazil, Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 74: Brazil, Neurological Disorder Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 75: Middle East, Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 76: Middle East, Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 77: Middle East, Neurological Disorder Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 78: Africa, Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 79: Africa, Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 80: Africa, Neurological Disorder Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 81: F. Hoffmann-La Roche Ltd Financial Performance
  • Figure 82: Bayer AG Financial Performance
  • Figure 83: Sanofi S.A. Financial Performance
  • Figure 84: AstraZeneca PLC Financial Performance
  • Figure 85: Abbott Laboratories Financial Performance

Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market Outlook 2025: Mapping Growth, Innovation, and Regional Shifts

Read More About Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market Outlook 2025: Mapping Growth, Innovation, and Regional Shifts

Global Vutrisiran Market Trends: Regional Breakdowns and Strategic Insights

Read More About Global Vutrisiran Market Trends: Regional Breakdowns and Strategic Insights

Vyndaqel Outlook 2034: Key Drivers, Trends, and Market Frontiers

Read More About Vyndaqel Outlook 2034: Key Drivers, Trends, and Market Frontiers

Functional Dyspepsia DrugMarket Overview 2025–2034: CAGR Trends, Long-Term Growth Paths, and Business Implications

Read More About Functional Dyspepsia DrugMarket Overview 2025–2034: CAGR Trends, Long-Term Growth Paths, and Business Implications

A 2025 analysis offering size estimates, growth trends and technological innovations in the live cell imaging microscopes market.

Read More About A 2025 analysis offering size estimates, growth trends and technological innovations in the live cell imaging microscopes market.

A 2025 market overview covering growth forecasts, treatment landscape, and key stakeholders in the isovaleric acidemia treatment market.

Read More About A 2025 market overview covering growth forecasts, treatment landscape, and key stakeholders in the isovaleric acidemia treatment market.

Discover key trends and market dynamics in the Mycobacterium Tuberculosis Market with 2025 insights from The Business Research Company.

Read More About Discover key trends and market dynamics in the Mycobacterium Tuberculosis Market with 2025 insights from The Business Research Company.

Discover key trends and market dynamics in the Smoking Cessation & Nicotine De-addiction Products Market with 2025 insights from The Business Research Company.

Read More About Discover key trends and market dynamics in the Smoking Cessation & Nicotine De-addiction Products Market with 2025 insights from The Business Research Company.

Central Nervous System Drugs Global Market Report 2022 – By Type (Analgesics, Anti-Parkinson Drugs, Anesthetics, Anti-Epileptics), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies/ Drug Stores), By Route O...

View Report

Cholinergic Drugs Global Market Report 2025 – By Type (Powder, Tablet, Capsule), By Drug Type (Muscarinic Agonists, Nicotinic Agonists, Acetylcholinesterase Inhibitors), By Indication (Alzheimer's Disease, Myasthenia Gra...

View Report

Rare Neurological Disease Treatment Global Market Report 2025 – By Drug Type (Biologics, Small Molecules), By Therapy (Cognitive Behavioral Therapy, Interpersonal Psychotherapy, Cyberknife, Other Therapies), By Mode Of A...

View Report

Alzheimer's Drugs Global Market Report 2025 – By Drugs (Donepezil, Rivastigmine, Galantamine, Memantine ), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy ), By Application (Early To Moderate...

View Report

Generic Central Nervous System Drugs Global Market Report 2025 – By Type (Multiple Sclerosis (MS), Anti-Psychotic, Analgesics, Anti-Parkinson Drugs, Anesthetics, Anti-Epileptics, Anti-Depressants, Other Types), By Drug C...

View Report

Epilepsy Drugs Global Market Report 2025 – By Seizure Type (Focal Seizures, Generalized Seizures, Non-Epileptic Seizures), By Generation Type (First Generation Anti-Epileptics, Second Generation Anti-Epileptics, Third Ge...

View Report

Antipsychotic Drugs Global Market Report 2025 – By Therapeutic Class (First Generation, Second Generation, Third Generation), By Disease (Schizophrenia, Bipolar Disorder, Unipolar Depression, Dementia, Other Diseases), B...

View Report

Neurological Disorder Drugs Global Market Report 2025 – By Drug Class (Cholinesterase Inhibitors, N-Methyl-D-Aspartate (NMDA) Receptor Antagonists, Antiepileptic, Antipsychotic And Antidepressant, Other Drugs Classes), B...

View Report

Frequently Asked Questions

Neurological disorder drugs refer to medications used to treat disorders of the nervous system. These disorders can affect the brain, spinal cord, and nerves throughout the body. The drugs aim to manage symptoms, slow the progression of the disorder, and improve the quality of life for individuals affected. For further insights on this market, request a sample here

The market major growth driver - Rising Neurological Disorders Drive Growth In Drugs Market. For further insights on this market, request a sample here

The neurological disorder drugs market size has grown strongly in recent years. It will grow from $84.6 billion in 2024 to $89.24 billion in 2025 at a compound annual growth rate (CAGR) of 5.5%. The growth in the historic period can be attributed to increasing animal testing and obtaining promising results, an increase in therapeutic treatments, the growth of neurological problems, government initiatives, and a growth in healthcare expenditure. The neurological disorder drugs market size is expected to see strong growth in the next few years. It will grow to " $110.99 billion in 2029 at a compound annual growth rate (CAGR) of 5.6%. The growth in the forecast period can be attributed to expanding therapeutic options and personalized therapies, a growing focus on disease-modifying treatments, the expanding use of digital biomarkers, and the increasing prevalence of neurological diseases. Major trends in the forecast period include advancements in drug design, advancements in neuroimaging, advancements in genetic research, collaborations and licensing agreements, and the emergence of regenerative medicine. For further insights on this market, request a sample here

The neurological disorder drugs market covered in this report is segmented –
1) By Drug Class: Cholinesterase Inhibitors, N-Methyl-D-Aspartate (NMDA) Receptor Antagonists, Antiepileptic, Antipsychotic And Antidepressant, Other Drugs Classes
2) By Indication: Epilepsy, Alzheimer’s Disease, Parkinson’s Disease, Multiple Sclerosis, Cerebrovascular Disease, Other Indications
3) By Route Of Administration: Oral, Parenteral, Other Routes Of Administration
4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Other Distribution Channels
5) By End-Users: Hospitals, Specialty Clinics, Homecare, Other End Users Subsegments:
1) By Cholinesterase Inhibitors: Donepezil, Rivastigmine, Galantamine
2) By N-Methyl-D-Aspartate (NMDA) Receptor Antagonists: Memantine, Other NMDA Receptor Antagonists
3) By Antiepileptic: Sodium Channel Blockers, GABA Enhancers, Glutamate Modulators, Other Antiepileptics
4) By Antipsychotic and Antidepressant: Risperidone, Olanzapine, SSRIs, SNRIs, Tricyclic
5) By Other Drug Classes: Dopaminergic Drugs, Alpha-2 Agonists, Immunomodulators, Other Neurological Disorder Medications For further insights on this market, request a sample here

North America was the largest region in the neurological disorder drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the neurological disorder drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. For further insights on this market, request a sample here.

Major companies operating in the neurological disorder drugs market are F. Hoffmann-La Roche Ltd, Bayer AG, Sanofi S.A, AstraZeneca PLC, Abbott Laboratories, Novartis AG, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company Pvt Ltd, Amgen Inc, Boehringer Ingelheim GmbH, Novo Nordisk A/S, Merck KGaA, Teva Pharmaceutical Industries Ltd, Otsuka America Pharmaceutical Inc, Biogen Inc, Bausch Health Companies Inc, Alexion Pharmaceuticals Inc., UCB S.A., Eisai Co Ltd, Cipla Inc, BioMarin Pharmaceutical Inc., Biocon Ltd, Acorda Therapeutics Inc.. For further insights on this market, request a sample here.

Major trends in this market include Innovative Approaches In Neurological Disorder Drugs Advancing Treatment For Multiple Sclerosis. For further insights on this market, request a sample here.

Customer representative image Book your 30 minutes free consultation with our research experts
Contact Us
Global Neurological Disorder Drugs Market Report 2025

Wait, we have a special offer for you! ✋

Get your exclusive 20% discount only on the Global Market Reports now using the code ONLINE20*

YES, get the discount! No, I'd pay the full price

*Copy paste the discount code in the cart

Back to top WhatsApp icon